Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence - PubMed (original) (raw)
. 2007 Oct;14(10):1759-67.
doi: 10.1038/sj.cdd.4402197. Epub 2007 Jul 6.
Affiliations
- PMID: 17612587
- DOI: 10.1038/sj.cdd.4402197
Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence
M Caron et al. Cell Death Differ. 2007 Oct.
Abstract
Lipodystrophic syndromes associated with mutations in LMNA, encoding A-type lamins, and with HIV antiretroviral treatments share several clinical characteristics. Nuclear alterations and prelamin A accumulation have been reported in fibroblasts from patients with LMNA mutations and adipocytes exposed to protease inhibitors (PI). As genetically altered lamin A maturation also results in premature ageing syndromes with lipodystrophy, we studied prelamin A expression and senescence markers in cultured human fibroblasts bearing six different LMNA mutations or treated with PIs. As compared to control cells, fibroblasts with LMNA mutations or treated with PIs had nuclear shape abnormalities and reduced proliferative activity that worsened with increasing cellular passages. They exhibited prelamin A accumulation, increased oxidative stress, decreased expression of mitochondrial respiratory chain proteins and premature cellular senescence. Inhibition of prelamin A farnesylation prevented cellular senescence and oxidative stress. Adipose tissue samples from patients with LMNA mutations or treated with PIs also showed retention of prelamin A, overexpression of the cell cycle checkpoint inhibitor p16 and altered mitochondrial markers. Thus, both LMNA mutations and PI treatment result in accumulation of farnesylated prelamin A and oxidative stress that trigger premature cellular senescence. These alterations could participate in the pathophysiology of lipodystrophic syndromes and lead to premature ageing complications.
Similar articles
- Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction.
Bidault G, Garcia M, Vantyghem MC, Ducluzeau PH, Morichon R, Thiyagarajah K, Moritz S, Capeau J, Vigouroux C, Béréziat V. Bidault G, et al. Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2162-71. doi: 10.1161/ATVBAHA.113.301933. Epub 2013 Jul 11. Arterioscler Thromb Vasc Biol. 2013. PMID: 23846499 - LMNA mutations resulting in lipodystrophy and HIV protease inhibitors trigger vascular smooth muscle cell senescence and calcification: Role of ZMPSTE24 downregulation.
Afonso P, Auclair M, Boccara F, Vantyghem MC, Katlama C, Capeau J, Vigouroux C, Caron-Debarle M. Afonso P, et al. Atherosclerosis. 2016 Feb;245:200-11. doi: 10.1016/j.atherosclerosis.2015.12.012. Epub 2015 Dec 20. Atherosclerosis. 2016. PMID: 26724531 - A homozygous mutation of prelamin-A preventing its farnesylation and maturation leads to a severe lipodystrophic phenotype: new insights into the pathogenicity of nonfarnesylated prelamin-A.
Le Dour C, Schneebeli S, Bakiri F, Darcel F, Jacquemont ML, Maubert MA, Auclair M, Jeziorowska D, Reznik Y, Béréziat V, Capeau J, Lascols O, Vigouroux C. Le Dour C, et al. J Clin Endocrinol Metab. 2011 May;96(5):E856-62. doi: 10.1210/jc.2010-2234. Epub 2011 Feb 23. J Clin Endocrinol Metab. 2011. PMID: 21346069 - LMNA-linked lipodystrophies: from altered fat distribution to cellular alterations.
Bidault G, Vatier C, Capeau J, Vigouroux C, Béréziat V. Bidault G, et al. Biochem Soc Trans. 2011 Dec;39(6):1752-7. doi: 10.1042/BST20110675. Biochem Soc Trans. 2011. PMID: 22103520 Review. - Prelamin A-mediated nuclear envelope dynamics in normal and laminopathic cells.
Lattanzi G. Lattanzi G. Biochem Soc Trans. 2011 Dec;39(6):1698-704. doi: 10.1042/BST20110657. Biochem Soc Trans. 2011. PMID: 22103510 Review.
Cited by
- LMNA Mutations G232E and R482L Cause Dysregulation of Skeletal Muscle Differentiation, Bioenergetics, and Metabolic Gene Expression Profile.
Ignatieva EV, Ivanova OA, Komarova MY, Khromova NV, Polev DE, Kostareva AA, Sergushichev A, Dmitrieva RI. Ignatieva EV, et al. Genes (Basel). 2020 Sep 7;11(9):1057. doi: 10.3390/genes11091057. Genes (Basel). 2020. PMID: 32906763 Free PMC article. - Detection of mesenchymal stem cells senescence by prelamin A accumulation at the nuclear level.
Bellotti C, Capanni C, Lattanzi G, Donati D, Lucarelli E, Duchi S. Bellotti C, et al. Springerplus. 2016 Aug 26;5(1):1427. doi: 10.1186/s40064-016-3091-7. eCollection 2016. Springerplus. 2016. PMID: 27625981 Free PMC article. - Variable Expressivity and Allelic Heterogeneity in Type 2 Familial Partial Lipodystrophy: The p.(Thr528Met) LMNA Variant.
Araújo-Vilar D, Fernández-Pombo A, Victoria B, Mosquera-Orgueira A, Cobelo-Gómez S, Castro-Pais A, Hermida-Ameijeiras Á, Loidi L, Sánchez-Iglesias S. Araújo-Vilar D, et al. J Clin Med. 2021 Apr 3;10(7):1497. doi: 10.3390/jcm10071497. J Clin Med. 2021. PMID: 33916827 Free PMC article. - Senolytics: Potential for Alleviating Diabetes and Its Complications.
Palmer AK, Tchkonia T, Kirkland JL. Palmer AK, et al. Endocrinology. 2021 Aug 1;162(8):bqab058. doi: 10.1210/endocr/bqab058. Endocrinology. 2021. PMID: 33705532 Free PMC article. Review. - Impaired differentiation of small airway basal stem/progenitor cells in people living with HIV.
Chung NPY, Khan KMF, Andreoli M, Kaner RJ, O'Beirne SL, Crystal RG. Chung NPY, et al. Sci Rep. 2022 Feb 22;12(1):2966. doi: 10.1038/s41598-022-06373-7. Sci Rep. 2022. PMID: 35194053 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous